Polaris Pharmaceuticals (6550TW) announced today that Dr. Philip Felgner of the University of California, Irvine will officially join the Polaris Technical Advisory Board on September 1.
CEO Mr. Chen said that Dr. Felgner will bring his decades of experience in mRNA technology and related contacts to Polaris, which will bring substantial and timely benefits to Polaris’ development and production of mRNA biopharmaceuticals.
Chairman Howard Chen also explained Polaris’s future strategic layout at Polaris’s shareholders meeting in August this year. He said that Polaris is very optimistic about the development potential of mRNA. mRNA can be used not only in vaccine development but also in new biological drugs. Chairman Howard Chen It is further stated that Polaris is gradually establishing an mRNA technical team. At present, it has mastered nearly 80% of mRNA-related technologies. Soon the company will have complete mRNA technology energy.
Dr. Philip Felgner is a Professor in the Department of Physiology and Biophysics at the University of California, Irvine, and Director of the Center for Vaccine Research and Development, where he studies the human immune response and how it applies to vaccine development.
Dr. Felgner has extensive pharmaceutical and academic experience in gene therapy. In 1987, he was the first to publish the application of cationic lipids for drug delivery technology in gene therapy. His invention was used to deliver mRNA to cells, and It is widely used in gene therapy in molecular and cell biology, and the drug delivery technology of mRNA vaccine products currently on the market for Covid 19 is also used in this regard. Dr. Felgner has been focusing on gene therapy research and vaccine development. He has published a lot of literature and a number of approved patents in this field, which has won international recognition.
Dr. Felger started his career in gene therapy research with Syntex Pharmaceuticals, where he was responsible for the development of vaccine drugs. He then served as Chief Scientist of Vical Inc. and was one of the founders of the company, leading the development of gene therapy drug delivery technologies and bringing the company’s DNA drugs from the R&D stage to clinical trials, making him a pioneer in the gene therapy industry at that time.
Dr. Felgner went on to found Gene Therapy Systems, Inc. as the company’s Chief Scienrific Officer to continue gene therapy technology research and development. After that, he moved to academia for research. He has been researching and teaching at the University of California, Irvine for nearly 20 years, and devoted himself to the work of immune system research and vaccine development. Dr. Felgner has led U.S. government-supported research programs for many years, acknowledging his leadership in nucleic acid vaccine development. Dr. Felgner graduated from the Department of Chemistry at Michigan State University, USA, and then obtained his master’s and doctoral degrees in biochemistry and neurology from the same school, and was awarded the Distinguished Alumni Award.